دورية أكاديمية
Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions.
| العنوان: | Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions. |
|---|---|
| المؤلفون: | Crescioli G; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.; Tuscan Regional Centre of Pharmacovigilance, Florence, Italy., Brilli V; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.; Toxicology Unit, Emergency Department, Careggi University Hospital, Florence, Italy., Lanzi C; Toxicology Unit, Emergency Department, Careggi University Hospital, Florence, Italy., Burgalassi A; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.; Toxicology Unit, Emergency Department, Careggi University Hospital, Florence, Italy., Ieri A; Toxicology Unit, Emergency Department, Careggi University Hospital, Florence, Italy., Bonaiuti R; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.; Joint Laboratory of Technological Solutions for Clinical Pharmacology, Pharmacovigilance and Bioinformatics, University of Florence, Florence, Italy., Romano E; Internal Medicine Unit 2, Emergency Department, Careggi University Hospital, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Innocenti R; Internal Medicine Unit 2, Emergency Department, Careggi University Hospital, Florence, Italy., Mannaioni G; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.; Toxicology Unit, Emergency Department, Careggi University Hospital, Florence, Italy., Vannacci A; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.; Tuscan Regional Centre of Pharmacovigilance, Florence, Italy.; Joint Laboratory of Technological Solutions for Clinical Pharmacology, Pharmacovigilance and Bioinformatics, University of Florence, Florence, Italy., Lombardi N; Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy. niccolo.lombardi@unifi.it.; Tuscan Regional Centre of Pharmacovigilance, Florence, Italy. niccolo.lombardi@unifi.it.; Toxicology Unit, Emergency Department, Careggi University Hospital, Florence, Italy. niccolo.lombardi@unifi.it. |
| المصدر: | Internal and emergency medicine [Intern Emerg Med] 2021 Apr; Vol. 16 (3), pp. 697-710. Date of Electronic Publication: 2020 Dec 23. |
| نوع المنشور: | Journal Article; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Italy NLM ID: 101263418 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1970-9366 (Electronic) Linking ISSN: 18280447 NLM ISO Abbreviation: Intern Emerg Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Milan : Springer Original Publication: Rome, Italy : CEPI-AIM Group, 2006- |
| مواضيع طبية MeSH: | Drug Interactions* , COVID-19 Drug Treatment*, Drug-Related Side Effects and Adverse Reactions/*epidemiology, Adult ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; Comorbidity ; Female ; Hospitalization ; Humans ; Italy/epidemiology ; Male ; Middle Aged ; Polypharmacy ; Prevalence ; Risk Factors ; SARS-CoV-2 |
| مستخلص: | Due to the need of early and emergency effective treatments for COVID-19, less attention may have been paid to their safety during the global emergency. In addition, characteristics of drug-drug interaction (DDI)-related adverse drug reactions (ADRs) in COVID-19 patients have not yet been studied in depth. The aim of the present case-series study is to describe clinical and pharmacological characteristics of SARS-CoV-2 hospitalised patients, focusing on ADRs, particularly those related to DDIs. We evaluated all reports of COVID-19 medication-related ADRs collected within the COVID-19 Units of Careggi University Hospital, Florence (Italy), between January 1st and 31st May 2020. Information regarding COVID-19 medications, patients' demographic and clinical characteristics, concomitant drugs, ADRs description and outcome, were collected. Each case was evaluated for the causality assessment and to identify the presence of DDIs. During the study period, 23 Caucasian patients (56.5% males, mean age 76.1 years) experienced one or more ADRs. The majority of them were exposed to polypharmacy and 17.4% presented comorbidities. ADRs were referred to cardiovascular, psychiatric and gastrointestinal disorders. The most frequently reported preferred term was QT prolongation (mean QT interval 496.1 ms). ADRs improved or resolved completely in 60.8% of cases. For all patients, a case-by-case evaluation revealed the presence of one or more DDIs, especially those related to pharmacokinetic interactions. Despite the small number of patients, our evidence underline the clinical burden of DDIs in SARS-CoV-2 hospitalised patients and the risk of unexpected and uncommon psychiatric ADRs. |
| التعليقات: | Comment in: Intern Emerg Med. 2021 Apr;16(3):797-798. (PMID: 33517559) Comment in: Intern Emerg Med. 2021 Apr;16(3):549-550. (PMID: 33713283) |
| References: | Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G (2020) Advances in the possible treatment of COVID-19: a review. Eur J Pharmacol 16:173372. (PMID: 10.1016/j.ejphar.2020.173372) Zhang XY, Huang HJ, Zhuang DL, Nasser MI, Yang MH, Zhu P et al (2020) Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty 9(1):99. (PMID: 10.1186/s40249-020-00691-6) Cui N, Zou X, Xu L (2020) Preliminary CT findings of coronavirus disease 2019 (COVID-19). Clin Imaging 65:124–132. (PMID: 10.1016/j.clinimag.2020.04.042) Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395(10223):497–506. (PMID: 10.1016/S0140-6736(20)30183-5) Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P (2020) An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sci 17(257):118105. (PMID: 10.1016/j.lfs.2020.118105) Arachchillage DRJ, Laffan M (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thrombosis Haemostasis: JTH 18(5):1233–1234. (PMID: 10.1111/jth.14820) Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thrombosis Haemostasis: JTH 18(5):1094–1099. (PMID: 10.1111/jth.14817) Chen ZR, Zhou Y, Liu J, Peng HW, Zhou J, Zhong HL et al (2020) Pharmacotherapics advice in guidelines for COVID-19. Front Pharmacol 11:950. (PMID: 10.3389/fphar.2020.00950) AIFA (2020) Farmaci utilizzabili per il trattamento della malattia COVID-19. https://www.aifagovit/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19 . Last accessed: 04 August 2020. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. (2020) Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect. Vinetz JM (2020) Lack of efficacy of hydroxychloroquine in covid-19. BMJ (Clinical research ed) 19(369):m2018. AIFA (2020) Idrossiclorochina nella terapia dei pazienti adulti con COVID-19. https://www.aifagovit/documents/20142/1123276/idrossiclorochina_22072020pdf/764add8f-f08f-0e26-df75-952986e54b8b . Last accessed: 04 August 2020. AIFA (2020) Darunavir/cobicistat nella terapia dei pazienti adulti con COVID-19. https://www.aifagovit/documents/20142/1123276/darunavir_cobicistat_17072020pdf/6e34d1cf-9d14-4e01-8229-6467de2da082 . Last accessed: 04 August 2020. AIFA (2020) Lopinavir/ritonavir nella terapia dei pazienti adulti con COVID-19. https://www.aifagovit/documents/20142/1123276/lopinavir_ritonavir_17072020pdf/ab9e07d8-585b-6eda-0007-a8f3d1e175c4 . Last accessed: 04 August 2020. Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, et al. (2020) Incidence of adverse drug reactions in COVID-19 patients in China: an active monitoring study by hospital pharmacovigilance system. Clin Pharmacol Therapeutics. Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D et al (2020) The impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance. Drug Saf 43(8):699–709. (PMID: 10.1007/s40264-020-00965-w) Mazzitello C, Esposito S, De Francesco AE, Capuano A, Russo E, De Sarro G (2013) Pharmacovigilance in Italy: an overview. J Pharmacol Pharmacother 4(Suppl 1):S20–S28. (PMID: 243479763853663) Lombardi N, Crescioli G, Bettiol A, Marconi E, Vitiello A, Bonaiuti R et al (2018) Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. BMC Pharmacol Toxicol 19(1):16. (PMID: 10.1186/s40360-018-0207-4) Lombardi N, Crescioli G, Bettiol A, Tuccori M, Rossi M, Bonaiuti R et al (2019) Vaccines safety in children and in general population: a pharmacovigilance study on adverse events following anti-infective vaccination in Italy. Front Pharmacol 10:948. (PMID: 10.3389/fphar.2019.00948) Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245. (PMID: 10.1038/clpt.1981.154) Drug Interactions Checker. https://www.drugscom/interaction/list/?drug_list . Last accessed: 04 August 2020. IBM Micromedex ® . https://www.micromedexsolutionscom/micromedex2/4340/WebHelp/Tools/Interactions/Drug_Interactions_severity_definitionshtm . Last accessed: 04 August 2020. Lombardi N, Bettiol A, Crescioli G, Ravaldi C, Bonaiuti R, Venegoni M, et al. (2020) Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments. Internal Emergency Med. Lombardi N, Crescioli G, Bettiol A, Tuccori M, Capuano A, Bonaiuti R et al (2020) Italian emergency department visits and hospitalizations for outpatients’ adverse drug events: 12-year active pharmacovigilance surveillance (The MEREAFaPS Study). Front Pharmacol 11:412. (PMID: 10.3389/fphar.2020.00412) Hult S, Sartori D, Bergvall T, Hedfors Vidlin S, Grundmark B, Ellenius J et al (2020) A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf 43(8):775–785. (PMID: 10.1007/s40264-020-00939-y) Laurence L. Brunton BAC, Bjorn C. Knollman (2011) Quinolines and related compounds. In: Brunton LL, (ed). Goodman and Gilman’s the pharmacological basis of therapeutics, Twelfth Edition 12th Edition. New York: McGraw-Hill Companies; p. Chapter 49; pp 1270–2. Venisse N (2020) Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundamental Clin Pharmacol. Kelly M, O’Connor R, Townsend L, Coghlan M, Relihan E, Moriarty M, et al. (2020) Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. Br J Clin Pharmacol. Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S et al (2015) Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opinion Drug Safety 14(2):295–303. (PMID: 10.1517/14740338.2015.989210) EMA. Kaletra—Annex I—Summary of product characteristics. https://www.emaeuropaeu/en/documents/product-information/kaletra-epar-product-information_enpdf . Last accessed: 04 August 2020. EMA. Prezista—Annex I—Summary of product characteristics. https://www.emaeuropaeu/en/documents/product-information/prezista-epar-product-information_enpdf . Last accessed: 04 August 2020. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE (2012) Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Sci World J 2012:212178. (PMID: 10.1100/2012/212178) Rajkumar RP (2020) COVID-19 and mental health: a review of the existing literature. Asian J Psychiatry 10(52):102066. (PMID: 10.1016/j.ajp.2020.102066) Tandon R (2020) The COVID-19 pandemic, personal reflections on editorial responsibility. Asian J Psychiatry 50:102100. (PMID: 10.1016/j.ajp.2020.102100) Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P et al (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7(7):611–627. (PMID: 10.1016/S2215-0366(20)30203-0) AIFA. Zitromax—Riassunto delle caratteristiche del prodotto. https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/cerca-per-principio-attivo?princ_att=Azitromicina . Accessed 4 Aug 2020. EMA. Relzosta—Annex I—Summary of product characteristics. https://www.emaeuropaeu/en/documents/product-information/rezolsta-epar-product-information_enpdf . Last accessed: 04 August 2020. EMA. Roactemra—Annex I—Summary of product characteristics. https://www.emaeuropaeu/en/documents/product-information/roactemra-epar-product-information_enpdf . Last accessed: 04 August 2020. Das EM, Mohan D (1981) Chloroquine-related depression. Indian J Psychiatry 23(2):184–185. (PMID: 220651373013174) Lovestone S (1991) Chloroquine-induced mania. Br J Psychiatry: J Mental Sci 159:164–165. (PMID: 10.1192/bjp.159.1.164b) Bogaczewicz A, Sobow T, Bogaczewicz J, Bienkowski P, Kowalski J, Wozniacka A (2016) Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment. Int J Dermatol 55(12):1378–1380. (PMID: 10.1111/ijd.13266) Bogaczewicz J, Sobow T, Bogaczewicz A, Robak E, Bienkowski P, Sysa-Jedrzejowska A et al (2014) Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus–a case report. Lupus 23(2):188–193. (PMID: 10.1177/0961203313513818) Emmanuel S, Ostlundh L (2020) Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic. Asian J Psychiatry 20(54):102203. (PMID: 10.1016/j.ajp.2020.102203) Bitta MA, Kariuki SM, Mwita C, Gwer S, Mwai L, Newton C (2017) Antimalarial drugs and the prevalence of mental and neurological manifestations: a systematic review and meta-analysis. Welcome Open Res 2:13. (PMID: 10.12688/wellcomeopenres.10658.2) Sato K, Mano T, Iwata A, Toda T (2020) Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends 14(2):139–143. (PMID: 10.5582/bst.2020.03082) Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C et al (2018) Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology 26(5):1141–1149. (PMID: 10.1007/s10787-018-0498-5) Turjanski NLGG (2005) Psychiatric side-effects of medications: recent developments. Adv Psychiatr Treat 11:58–70. (PMID: 10.1192/apt.11.1.58) Winston A, Fatkenheuer G, Arribas J, Hill A, van Delft Y, Moecklinghoff C (2020) Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. HIV Clin Trials 11(3):163–169. (PMID: 10.1310/hct1103-163) Pfefferbaum B, North CS (2020) Mental health and the Covid-19 pandemic. New England J Med 383(6):510–512. (PMID: 10.1056/NEJMp2008017) Ravaldi C, Wilson A, Ricca V, Homer C, Vannacci A (2020) Pregnant women voice their concerns and birth expectations during the COVID-19 pandemic in Italy. Women Birth: J Australian College Midwives. Matvienko-Sikar K, Meedya S, Ravaldi C (2020) Perinatal mental health during the COVID-19 pandemic. Women Birth: J Australian College Midwives 33(4):309–310. (PMID: 10.1016/j.wombi.2020.04.006) FDA. PLAQUENIL® HYDROXYCHLOROQUINE SULFATE, USP. https://www.accessdatafdagov/drugsatfda_docs/label/2007/009768s041lblpdf . Last accessed: 04 Agust 2020. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z et al (2020) Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69(6):997–1001. (PMID: 10.1136/gutjnl-2020-321013) |
| فهرسة مساهمة: | Keywords: Adverse drug reactions; COVID-19; Drug–drug interactions; Internal medicine; Pharmacovigilance |
| تواريخ الأحداث: | Date Created: 20201228 Date Completed: 20210422 Latest Revision: 20221207 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7755981 |
| DOI: | 10.1007/s11739-020-02586-8 |
| PMID: | 33355896 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1970-9366 |
|---|---|
| DOI: | 10.1007/s11739-020-02586-8 |